XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 151 filers reported holding XENON PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 3.19 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,240,548 | -11.3% | 1,178,002 | 0.0% | 1.08% | -0.1% |
| Q2 2023 | $45,353,077 | +7.6% | 1,178,002 | 0.0% | 1.08% | +7.3% |
| Q1 2023 | $42,160,692 | -9.1% | 1,178,002 | +0.2% | 1.01% | -9.8% |
| Q4 2022 | $46,356,747 | +11.1% | 1,175,672 | +1.7% | 1.12% | +3.4% |
| Q3 2022 | $41,730,000 | +22.1% | 1,155,961 | +2.9% | 1.08% | +8.3% |
| Q2 2022 | $34,180,000 | +32.7% | 1,123,604 | +33.4% | 1.00% | +53.5% |
| Q1 2022 | $25,755,000 | +6.9% | 842,498 | +9.2% | 0.65% | +16.3% |
| Q4 2021 | $24,098,000 | +170.5% | 771,367 | +32.3% | 0.56% | +197.9% |
| Q3 2021 | $8,910,000 | -16.4% | 583,100 | +1.9% | 0.19% | -11.4% |
| Q2 2021 | $10,660,000 | +4.0% | 572,500 | 0.0% | 0.21% | -5.8% |
| Q1 2021 | $10,248,000 | +29.4% | 572,500 | +11.2% | 0.22% | +33.3% |
| Q4 2020 | $7,921,000 | +38.7% | 515,000 | -0.1% | 0.17% | +15.9% |
| Q3 2020 | $5,709,000 | -11.7% | 515,711 | 0.0% | 0.14% | -18.1% |
| Q2 2020 | $6,467,000 | +14.1% | 515,711 | +3.1% | 0.18% | -24.4% |
| Q1 2020 | $5,670,000 | – | 500,000 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |